Twist Bioscience’s chief accounting officer sells shares worth $9,130

Robert F. Werner, the Chief Accounting Officer of Twist Bioscience Corp (NASDAQ:TWST), a $3.2 billion market cap biotechnology company with strong recent momentum showing a 43% return over the past year, recently sold 185 shares of the company’s common stock. The shares were sold on February 3, 2025, at an average price of $49.352 each, totaling approximately $9,130. Following this transaction, Werner holds 52,858 shares directly. The company maintains a healthy liquidity position with a current ratio of 4.96x, indicating strong ability to meet short-term obligations.

The sale was conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units, as mandated by the company’s equity incentive plans. This "sell to cover" transaction was not a discretionary trade by Werner. According to InvestingPro, the stock shows notable price volatility, with additional insights available in the comprehensive Pro Research Report.

In other recent news, Twist Bioscience has been experiencing a flurry of positive analyst attention. Scotiabank (TSX:BNS) raised the company’s target to $62, maintaining a Sector Outperform rating, following Twist Bioscience’s Q1 2025 financial results that exceeded consensus predictions. The company’s full-year fiscal 2025 guidance was also revised upward, with expectations for total revenue growth of 19-21% year-over-year.

Barclays (LON:BARC) analyst Luke Sergott increased the target on Twist Bioscience shares from $52.00 to $58.00, reiterating an Overweight rating. Sergott’s optimism is fueled by the company’s growing momentum, particularly in its Express portfolio and Next-Generation Sequencing (NGS) tools.

Baird reaffirmed its positive stance on Twist Bioscience, maintaining an Outperform rating and a $48.00 price target. The firm’s analyst highlighted the consistent pricing premiums for the company’s Express Genes service, suggesting strong demand for the company’s offerings.

TD Cowen reaffirmed a Buy rating and a price target of $58.00, signaling confidence in the company’s revenue and gross margin outlook for fiscal year 2025 and beyond. Finally, following a strong performance in FY24, Twist Bioscience received an updated price target from Scotiabank, raising it to $54 from $50, maintaining a Sector Outperform rating. These are recent developments that have caught the attention of investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.